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Fungi strike back when attacked
Fungi are ubiquitous on earth and are essential for the maintenance of the global ecological
equilibrium. Despite providing benefits to living organisms, they can also target specific hosts
and inflict damage. These fungal pathogens are known to affect, for example, plants and mam-
mals and thus reduce crop production necessary to sustain food supply and cause mortality in
humans and animals. Designing defenses against these fungi is essential for the control of food
resources and human health. As far as fungal pathogens are concerned, the principal option
has been the use of antifungal agents, also called fungicides when they are used in the
environment.
Commercial antifungal agents and fungicides belong to several classes and affect several cel-
lular functions (Fig 1) [1]. Fungicides outnumber medical antifungal agents by the number of
chemical classes and by the number of licensed drugs [1]. Exposing plant and/or human path-
ogens to these agents results in a substantial fungal growth deficiency and eventually clearance
of the pathogens in the infected sites or infected host. However, the same exposure imposes
strong selective pressures for the development of resistance, which is ineluctably acquired over
short- and long-term periods. Fungicides that are spread in the environment can also cause
the selection of resistance in ubiquitous fungi that are also human pathogens. The transmis-
sion of environmentally acquired resistance to human is of concern because it reduces the lim-
ited number of possible treatments to a few alternatives.
It is important to resolve resistance mechanisms because they may highlight not only novel
biology but also may reveal novel strategies to counteract and combat resistance. Resistance
mechanisms can be grouped in at least three general principles that include (i) decrease of
effective intracellular drug concentration, (ii) alterations of the drug target, and (iii) compensa-
tory mechanisms which decrease drug toxicity [2]. I will summarize here approaches that led
to the understanding of antifungal resistance in plant and human fungal pathogens with a spe-
cial focus on genome-wide studies.
Reverse and forward genetics to understand drug resistance
Genome-wide studies performed on the yeast Saccharomyces cerevisiae have been crucial to
decipher the mode of action of drugs and associated resistance mechanisms [3]. These studies
are based on reverse genetics with the use of mutant collections and/or overexpression collec-
tions that can be scaled to high throughput screenings [4]. Genetic screenings can reveal not
only the principal target of antifungal agents but also identify off-targets which constitute
genetic networks that are affected by drug exposure [5]. Several examples of such genetic
screens have been reported in human fungal pathogens. In Candida albicans, homozygous and
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heterozygous mutant collections (a total of 3,030 mutants) were used to identify gene networks
that contribute to resistance to candins. In the same species, overexpression of all transcription
factors of a specific family (zinc cluster family) helped to identify novel mediators of azole
resistance [6]. In C. glabrata, a collection of deletion mutants (619) was used to identify genes
critical for azole and candin stress [7]. In Cryptococcus neoformans, a collection of transcrip-
tion factor mutants (322) explored gene networks mediating resistance to azoles, polyenes,
and 5-fluorocytosine [8].
Forward genetics and the systematic generation of drug-resistant mutants can also be used
to discover the mode of action of drugs. The identification of the mutation(s) responsible for
the drug resistance phenotype can be addressed by classical genetic analysis of the mutants.
This requires, however, several lengthy processes, including, for example, back-crosses with
tester strains and/or complementation tests with whole-genome libraries [9]. A classic example
in early studies is the discovery of the targets of rapamycin using mutants generated in S. cere-
visiae [10].
This classical forward genetic approach can now be greatly facilitated by whole-genome
sequence analysis. With the technical advances of DNA sequencing technologies, whole
genomes can now be sequenced with high efficiency and at low cost. As early as 2008, the use
of a whole-genome approach (by pyrosequencing) addressed the occurrence of spontaneous
mutations in S. cerevisiae [11]. This study was followed in 2010 by another genome-scale study
(using pyrosequencing) in S. cerevisiae that identified gain of function alleles of peroxiredoxin
Fig 1. Cellular targets of principal antifungals used in medicine and in agriculture. The cited antifungals and fungicides have the
following mode of action: polyenes bind ergosterol; phenylpyrroles and dicarboximides inhibit MAP/histidine-kinases; azoles and
morpholines target 14α-lanosterol demethylase and both sterol Δ14-reductase and Δ8-Δ7-isomerase, respectively (both chemical
classes are used in medicine and in the environment); allylamines target squalene epoxidase; pyrimidine analogues interfere with
nucleic acid biosynthesis whereas phenylamides target RNA polymerase I; benzimidazoles bind to b-tubulin; strobilurins and
succinate dehydrogenase inhibitors inhibit both the electron transfer chain of mitochondrial respiration by inhibiting complex III
and complex II, respectively; anilinopyrimidines target mitochondrial signaling pathways; candins target the biosynthesis of β-1,3
glucans. MAP, Mitogen-activated protein.
https://doi.org/10.1371/journal.ppat.1007478.g001
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(TSA1) which conferred resistance to oxidative stress [12]. Elucidation of drug resistance
mechanisms has recently progressed by the use of hypermutator strains in S. cerevisiae lacking
a functional MSH2 gene [13]. This gene participates in DNA mismatch repair, and when its
activity is decreased either by mutations or gene inactivation, it induces an increased rate of
spontaneous mutations or drug-induced mutations [14]. The study of Ojini and colleagues
[13] exploited this property to generate mutants resistant to several drugs including canava-
nine, camptothecin, and several anticancer drugs. Systematic genome sequencing of drug-
resistant mutants revealed mutations in genes critical for drug resistance, e.g., CAN1 for cana-
vanine and TOP1 for camptothecin [13]. The use of hypermutator S. cerevisiae strains with an
MSH2 defect followed by whole-genome sequencing was recently used to identify the gene
(ERG6) targeted by the natural antifungal compound tomatidine [15]. These drug resistance
mapping studies underline the great potential of whole-genome sequencing. This specific use
of genome sequencing is, however, only a small fraction of the vast majority of other genome
sequencing studies performed with fungi that were aimed to resolve population genetic struc-
tures in S. cerevisiae [16] or even C. albicans [17].
Genome-wide studies to understand drug resistance in fungal
pathogens
Drug-resistant fungal pathogens originating from the environment or from the clinic consti-
tute an immense resource for understanding antifungal drug resistance mechanisms. Whole-
genome sequence data and downstream analysis give unique opportunities to identify different
types of mutations, including single nucleotide polymorphisms (SNPs), insertions, deletions,
or structural variations (gene or chromosome copy variations including aneuploidies)
involved in drug resistance. At least two approaches can deliver suitable candidate nucleotide
positions in genome-wide analysis. The first is inspired by human genetics and makes use of
genome-wide association studies (GWAS). Quantitative trait loci (QTLs) analysis is also aimed
at resolving the relationships between phenotypes and genotypes but not at the nucleotide res-
olution level of GWAS. The basic principle of GWAS is to screen diverse populations for phe-
notypic differences between individuals. Although many GWAS performed on fungal plant
pathogens have focused on resistance to host factors [18], a few have addressed the identifica-
tion of drug resistance genes with this approach. A landmark study was published by Mohd-
Assaad and colleagues [19], in which azole resistance was investigated in Rhynchosporium com-
mune, the causal agent of the barley scald disease. The study used whole-genome data from a
set of 120 isolates and identified CYP51A mutations (the target of azoles) and several other loci
(YVC1, a calcium channel, a transcription activator, and a saccharopine dehydrogenase) that
also contributed to azole resistance. Another GWAS [20] on Fusarium graminearum (a fungus
causing Fusarium head blight) mapped several phenotypes, including azole resistance. It is
important to note that the genome data obtained here were from 119 isolates through restric-
tion site-associated DNA sequencing (RADseq), which can provide a large number of SNP
markers but at a lower resolution than whole-genome sequencing using high-throughput
methods. The study identified 51 genes associated with propiconazole sensitivity in wild-type
strains phenotyped under natural field conditions. This provided useful insights into non-
CYP51A mediated resistance mediators. It is likely that other GWAS will emerge in the future;
even if GWAS show great potential, they also have significant limitations. The structure of the
investigated populations is of critical importance. For example, GWAS are more likely to suc-
ceed if (i) the investigated population is undergoing sexual recombination, (ii) the number of
isolates originates from diverse conditions, and (iii) the number of investigated isolates is
above a threshold of approximately 100 isolates [21]. Fungal species, including C. albicans [17]
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and C. glabrata [22] or filamentous fungi such as Aspergillus fumigatus [23], have marginal or
absent sexual reproduction. Therefore, the power of GWAS is predicted to be limited in these
clonal species. Despite this limitation, GWAS was successfully undertaken in a study of 387 C.
neoformans var. grubii genomes and identified 10 loci associated with virulence capacity [24].
The study also investigated melanization in these isolates and identified a loss of function in
BZP4, which is a transcription factor required to produce melanin, a molecule necessary for
maintaining Cryptococcus virulence [24]. Another study performed on only 20 C. albicans iso-
lates linked host-associated phenotypic traits with individual loci in the genome. A nonfila-
mentous isolate exhibited a nonsense mutation in EFG1, a gene involved in yeast-to-hyphae
transition [25].
Finding the needle in a haystack
Genome-wide studies aimed to resolve drug resistance mechanisms on human pathogens are
using in their majority genome comparisons between investigated isolates. The included iso-
lates involve sometimes isogenic strains or strains with a high degree of relatedness. Studies
enumerated in Table 1 give an overview of genome-based approaches available so far to under-
stand drug resistance in fungal pathogens of clinical importance. A first aspect to consider is
whether genomic data were obtained via de novo genome assemblies or through read align-
ments to reference genomes. De novo assemblies can capture genomic rearrangements and
resolve individual gene copy number variations that could mediate drug resistance, which is
beneficial for these purposes as compared to read alignments to reference genomes. On the
other hand, whole chromosome or segmental aneuploidies can be the cause of drug resistance
as reported in C. albicans [26] and C. neoformans [27]. These changes can be readily detected
using read alignment strategies. Most of the genome data obtained in the studies from Table 1
are the results of read alignments, with the exception of specific C. auris and C. glabrata
genome comparisons [28,29].
Given that genome comparisons yield in most cases a large number of SNPs and/or indels,
a major challenge is to identify the nucleotide alterations associated with drug resistance. For
example, in a study in which 17 related sequential C. albicans isolates with increasing azole
resistance (over a 23-month period) were analysed, 4,610 nonsynonymous SNPs accumulated
compared to the initial susceptible isolate [30]. Without expert eyes, it is a daunting task to
deduce SNPs associated with drug resistance among other SNPs resulting from host adapta-
tions or simply genetic hitchhiking. Comparisons with genes known to be involved in azole
resistance is the approach of choice when attempting to detect SNPs relevant for drug resis-
tance. Alternatively, traditional genetics may be helpful in this task: the work of Losada and
colleagues [31] showed that it is possible to cross A. fumigatus in vitro to generate drug-resis-
tant isolates with isogenic susceptible isolates of opposite mating type and then to select result-
ing drug resistant progenies for genome analysis. Therefore, the number of SNPs not relevant
for drug resistance is reduced, speeding up the discovery of drug resistance associated SNPs.
However, there are a number of genome studies in which the divergence between susceptible
and resistant isolates is not as extensive, which facilitates the detection of SNPs associated with
drug resistance. For example, Branco and colleagues [32] obtained two related C. parapsilosis
isolates, one of which was azole-resistant, and identified two heterozygous SNPs and one
homozygous SNP, the latter in a gene encoding the C-5 sterol desaturase (ERG3). The resulting
nonsynonymous mutation yielded a nonfunctional Erg3 protein, which triggered azole resis-
tance. Of note is that the azole-resistant isolate was generated in vitro thus shortcutting the
accumulation of unrelated (i.e., host adaptation) mutations in the genome. On the other hand,
the study published by Vale-Silva and colleagues [29] used two clinical C. glabrata isolates, one
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Table 1. Genome-wide studies from antifungal drug-resistant isolates.
Fungal species
(ploidity)
Number of
investigated isolates
Genome sequencing
technology/Bioproject/SRA/
ENA
Major findings Antifungal class Genetic validation of
identified SNPs
Reference
C. albicans
(2n)
43a Base paired-end Illumina
sequencing/ PRJNA257929
• LOHs associated with drug
resistance
• ERG11 and TAC1 SNPs
azoles no [30]
C. albicans
(2n)
1 Illumina HiSeq platform/
PRJNA194436
• ERG2 loss of function
(retrotransposon insertion)
• ERG6 loss of function (SNP)
Amphotericin B yes [37]
C. albicans
(2n)
6 454 Sequencing Systemb • FKS1 SNP
• ERG3 SNPs
Echninocandins
Azoles
no [38]
C. albicans
(2n)
5 MiSeq sequencing (Illumina)/
NA
• TAC1, MRR1, ERG11, ERG3,
UPC2 SNPs
Azoles no [39]
C. auris
(1n)
25 Illumina HiSeq 2500/ MinION/
PRJNA392455
• ERG11 SNP
• FKS1 SNP
• FUR1 SNP
Azoles
Echinocandins
5-FC
no [40]
C. auris
(1n)
47 Pacbio/Illumina HiSeq/
PRJNA328792
• ERG11 SNPs Azoles no [28]
C. auris
(1n)
52 Illumina HiSeq 2500/NA • utg5_821828 (FLO8) SNP Amphotericin B no [41]
C. glabrata
(1n)
2 Illumina Genome Analyzer II
platform/ SRA047280.2
• FKS2 SNP
• CDC6 SNPs
Echinocandins yes [42]
C. glabrata
(1n)
3 454 Sequencing Systemb • FKS1, FKS2 SNPs
• CgPDR1 SNPs
Echninocandins
Azoles
no [38]
C. glabrata
(1n)
12 Illumina NextSeq 500 platform/
PRJNA310957
• FKS1 and FKS2 SNPs
• CgPDR1 SNPs
Echinocandins
Azoles
no [43]
C. glabrata
(1n)
1 Ion Torrent/PRJEB15305 • CgPDR1 SNP Azoles no [44]
C. glabrata
(1n)
2 PacBio/ PRJNA374542 • CgPDR1 SNP Azoles yes [29]
C. parapsilosis
(2n)
2 Ion Torrent/PRJNA361149 • ERG3 SNP Azoles yes [45]
C. parapsilosis
(2n)
2 Illumina HiSeq 4000/
SRP077071
• ERG3 SNP Azoles yes [32]
C. lusitaniae
(1n)
20 Illumina NextSeq500/
PRJNA433226
• MRR1 SNPs Azoles yes [33]
C. tropicalis
(2n)
1 Illumina HiSeq platform/
PRJNA194436
• ERG3 loss of function (SNP)
• ERG11 loss of function (170
bp deletion)
Amphotericin B yes [37]
A. fumigatus
(1n)
24 Illumina HiSeq 2500/
PRJEB8623
• CYP51A SNPs Azoles no [46]
A. fumigatus
(1n)
13 Illumina NextSeq 500 platform/
NA
• CYP51A SNPs Azoles no [47]
A. fumigatus
(1n)
2 Illumina Genome Analyzer II/
ERP001097
• HapE SNP Azoles yes [48]
A. fumigatus
(1n)
37c Illumina Genome Analyzer II/
PRJNA237785
• CYP51A SNPs
• ERG25 SNP
• GanA SNP
Azoles no [31]
(Continued)
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of which developed azole resistance in a patient within a 50-day time lapse. The azole-resistant
isolate accumulated only 17 nonsynonymous mutations, among which one was in the regula-
tor CgPDR1 known to mediate azole resistance. Very recently, comparative genome analysis
helped to reveal an unexpected isolate diversity in C. lusitaniae isolates recovered from a single
cystic fibrosis patient: the genomes of 20 different azole-resistant C. lusitaniae isolates from
this patient revealed, among identified SNPs (24–131 between any two isolates) and indels
(76–179 between any two isolates), accumulation of several distinct nonsynonymous SNPs in
the transcription factor MRR1. This transcription factor is known to mediate azole resistance
by upregulation of an efflux transporter [2], and therefore, the identified MRR1 SNPs were
likely to explain the occurrence of azole resistance in this species [33].
Further steps
Other genome-wide analyses can be envisaged to correlate genotypes with phenotypes. One of
them is the use of expression quantitative trait loci (eQTLs). eQTLs are naturally occurring
genetic polymorphisms controlling gene expression levels; these analyses have proved to be a
powerful approach for providing comprehensive data to interpret the link between genome
variations and specific phenotypes [34]. This relatively novel approach has not yet been used
in fungi-oriented studies; however, now that population-wide studies at the genome-scale are
becoming popular, it promises to lead to interesting and novel findings.
In any of the discussed cases here, evidence is required to show the causal link between
drug resistance and the candidate SNPs and/or indels identified by genome-wide studies. This
supporting step has not been systematically addressed in the studies listed in Table 1. Nowa-
days, with the emerging technologies of gene editing (CRISPR [clustered regularly interspaced
short palindromic repeats]-Cas9 [CRISPR-associated 9]), this task can be undertaken in sev-
eral important fungal pathogens [35].
It is likely that in the future, more genome-based studies will emerge from fungal popula-
tion analysis. Genome comparisons with known SNPs involved in drug resistance will still be
the priority approach. Such comparisons may be facilitated by the creation of database
resources, in which all known drug resistance genes and their allelic variants are deposited.
This idea is currently attempted [36]; however, it should be strengthened by a strong commit-
ment by the scientific community.
Table 1. (Continued)
Fungal species
(ploidity)
Number of
investigated isolates
Genome sequencing
technology/Bioproject/SRA/
ENA
Major findings Antifungal class Genetic validation of
identified SNPs
Reference
Cryptococcus
deuterogattii
(1n)
4c NA/PRJNA387047 • FRR1 SNPs FK506/
rapamycin
yes [49]
a Paired isolates from 11 patients.
b Six drug resistance genes were amplified from six isolates and sequenced in a single run.
c Experimental in vitro adaptation.
Abbreviations: CDC6: cell division cycle 6; CgPDR1: Candida glabrata Pleiotropic drug resistance 1; CYP51A: 14α-lanosterol demethylase; ENA,; ERG2: C-8 sterol
isomerase; ERG3: C-5 sterol desaturase; ERG6: Delta(24)-sterol C-methyltransferase; ERG11: 14α-lanosterol demethylase; ERG25: C-4 methyl sterol oxidase; FKS1:
1,3-beta-D-glucan synthase 1; FKS2: 1,3-beta-D-glucan synthase 2; FLO8: Floculation gene 8; FRR1: FK506-binding protein 1; FUR1: Uracil phosphoribosyltransferase;
GanA: G protein alpha subunit; HapE: CCAAT transcription factor; LOH, los of heterozygosity; MRR1: Multidrug resistance regulator 1; NA, not available; SNP, single
nucleotide protein; TAC1: Transcriptional activator of CDR genes; UPC2: Sterol uptake control protein 2; SRA: Sequence Read Archived; ENA: European Nucleotide
Archive.
https://doi.org/10.1371/journal.ppat.1007478.t001
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